Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that having MNC stocks in your portfolio is an assurance of growth ...